Diseases [C] » Nutritional and Metabolic Diseases [C18] » Metabolic Diseases » Glucose Metabolism Disorders » Hyperinsulinism » Insulin Resistance
Phenomena and Processes [G] » Physiological Phenomena [G07] » Pharmacological and Toxicological Phenomena » Pharmacological Phenomena » Drug Resistance » Insulin Resistance
Description
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS. MeSH
Hierarchy View
Subtype Terms (1)
Metabolic Syndrome
329 drugs (116 approved, 213 experimental)
Phase 4 Indicated Drugs (57)
Phase 3 Indicated Drugs (18)
Phase 2 Indicated Drugs (42)
Phase 1 Indicated Drugs (33)
Other Experimental Indicated Drugs (129)
Organization Involved with Phase 4 Indications (136)
Agency for Science, Technology and Research
AGUNCO Obstetrics and Gynecology Centre
Aristotle University of Thessaloniki
Brain & Behavior Research Foundation
Carl T. Hayden Medical Research Foundation
Case Western Reserve University
Catholic University of Sacred Heart, Rome
Children's Hospital Research Institute of Manitoba
Chinese Academy of Medical Sciences
Hellenic Society of Hypertension
Hospital General de México Dr. Eduardo Liceaga
Hospital Regional Alta Especialidad Bajio
Icahn School of Medicine at Mount Sinai
Indian Council of Medical Research
Kessler Institute for Rehabilitation
King Edward Medical University
Martinos Center for Biomedical Imaging
Mountain Diabetes and Endocrine Center
National Cheng Kung University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of Mental Health (NIMH)
National Institutes of Health (NIH)
National Natural Science Foundation of China
People's Liberation Army of China
Postgraduate Institute of Medical Education and Research
Singapore Clinical Research Institute
Sitaram Bhartia Institute of Science and Research
State University of New York, Brooklyn
State University of New York, Buffalo
The Depressive and Bipolar Disorder Alternative Treatment Foundation
The University of Texas, Dallas
Ukrainian Medical Stomatological Academy
Organization Involved with Phase 3 Indications (78)
Bambino Gesù Hospital and Research Institute
Bethesda Diabetes Research Center
Building Interdisciplinary Research Careers in Women's Health
French National Agency for Research on AIDS and Viral Hepatitis
Instituto Mexicano del Seguro Social
Jaeb Center for Health Research
Juvenile Diabetes Research Foundation
National Center for Advancing Translational Science (NCATS)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute for Health Research, United Kingdom
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Aging (NIA)
Oklahoma Medical Research Foundation
Shriners Hospitals for Children
Stanley Medical Research Institute
St. Antonius Hospital, Nieuwegein
Taichung Veterans General Hospital
Translational Research Institute for Metabolism and Diabetes, Florida
UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France
Organization Involved with Phase 2 Indications (92)
Advance Foods and Materials Network
Allegheny Singer Research Institute
Arizona Department of Health Services
Canadian Institutes of Health Research (CIHR)
Centro Hospitalar de Vila Nova de Gaia/Espinho
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Hoosier Cancer Research Network
Institut National de la Santé Et de la Recherche Médicale, France
Kenney & Ross Limited, Nova Scotia
Laboratorios Silanes S.A. de C.V.
National Center for Complementary and Integrative Health (NCCIH)
National Center for Research Resources (NCRR)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Child Health and Human Development (NICHD)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Northern Ontario School of Medicine
Office of Dietary Supplements (ODS)
Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences
South-Eastern Norway Regional Health Authority
The John A. Hartford Foundation
University Hospital of North Norway
Organization Involved with Phase 1 Indications (27)
Organization Involved with Other Experimental Indications (143)
Biotechnology and Biological Sciences Research Council
Bogomolets National Medical University
Centre de Recherche en Nutrition Humaine Rhone-Alpe
Clinica Universidad de Navarra
Diabetes Action Research and Education Foundation
Dutch Diabetes Research Foundation
ediatric Hospital CMN Siglo XXI
Federal University of Health Science of Porto Alegre
Federal University of Mato Grosso do Sul
Federal University of Rio de Janeiro
Foundation for Research Science and Technology, New Zealand
Fundação de Amparo à Pesquisa do Estado de São Paulo
Garvan Institute of Medical Research
German Institute of Human Nutrition
HSC Research & Development Division, Public Health Agency, Northern Ireland
Illinois Institute of Technology
Institute of Liver and Biliary Sciences, India
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes
Katholieke Universiteit Leuven
Midwest Biomedical Research Foundation
Nanjing University of Traditional Chinese Medicine
National Institute of General Medical Sciences (NIGMS)
Pennington Biomedical Research Center
Pontificia Universidad Catolica de Chile
Rio de Janeiro State University
Steno Diabetes Center Copenhagen
St. Luke's-Roosevelt Hospital Center
Supreme Council Of Health, Qatar
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
